新藥進入台灣自費市場的潛力與策略優化研究

Abstract

台灣自費藥品市場因創新療法的高成本與國民健康保險（NHI）框架的限制而面臨重大挑戰。本研究聚焦於Ho-Ning平台的發展與影響，該平台是一個基於雲端的解決方案，旨在解決運營低效問題，優化患者協助計畫（PAP）與患者支持計畫（PSP），並促進利益相關者的合作。 Ho-Ning平台作為一個集中式數位中介，整合了製藥公司、藥局與患者。該平台利用人工智慧驅動的分析，優化資源分配、降低運營成本並改善患者的用藥依從性。其核心功能包括藥局的即時庫存管理、製藥公司的匿名患者數據分析，以及為患者提供透明的成本溝通，這些創新旨在賦能利益相關者並簡化自費藥品流程。 SWOT分析強調了台灣自費藥品市場的增長機遇，以及該平台克服如利益相關者未對齊與有限數位採用率等系統性障礙的能力。財務預測顯示，平台於第四年實現盈利，收入來源包括訂閱費用、PAP服務與數據洞察。通過將技術創新與以患者為中心的護理相結合，Ho-Ning平台致力於重塑台灣的自費藥品生態系統，提升信任、效率與協作水平。

Taiwan’s self-pay pharmaceutical market faces critical challenges due to high-cost innovative therapies and the limitations imposed by the National Health Insurance (NHI) framework. This study explores the development and impact of the Ho-Ning platform, a cloud-based solution designed to address operational inefficiencies, streamline Patient Assistance Programs (PAP) and Patient Support Programs (PSP), and enhance stakeholder collaboration. The Ho-Ning platform serves as a centralized digital intermediary that integrates pharmaceutical companies, pharmacies, and patients. It leverages AI-driven analytics to optimize resource allocation, reduce operational costs, and improve medication adherence. Key features include real-time inventory management for pharmacies, anonymized patient data analysis for pharmaceutical companies, and transparent cost communication for patients. These innovations aim to empower stakeholders while simplifying the self-pay process. A SWOT analysis highlights the growing opportunities in Taiwan’s self-pay market and the platform's ability to overcome systemic barriers such as stakeholder misalignment and limited digital adoption. Financial projections show profitability by the fourth year, driven by revenue from subscription fees, PAP services, and data insights. By aligning technological innovation with patient-centered care, the Ho-Ning platform aspires to redefine Taiwan’s self-pay pharmaceutical ecosystem, fostering trust, efficiency, and collaboration among all stakeholders.